Melanoma, Malignant Familial Intraocular

Watchlist

(log in to enable)

Retrieved

2019-09-22

Source

Omim

Trials

—

Genes

CDKN2A, MC1R, MGMT, CDK4, CDKN2B, ACD, TERF2IP, POT1, BAP1, TERT, MITF, H3P10, CMM, IFNA13, IFNA2, IFNA1, HRAS, IFN1@, IFNA17, XPA, CHRM1, HPRT1, XRS, TP53, TYR, PTH, NPPA, MYCL, CDK2, BRCA2

Drugs

Aldesleukin ( PROLEUKIN ), HLA-A2 restricted CD8 T-cell line expressing MART-1 T-cell receptor, Imexon

Aldesleukin ( PROLEUKIN ), HLA-A2 restricted CD8 T-cell line expressing MART-1 T-cell receptor, Imexon, Melphalan ( EVOMELA, ALKERAN ), Oblimersen

Interested in hearing about new therapies?

Bowen et al. (1964) reported malignant intraocular melanoma in a 45-year-old white female and her 26-year-old daughter. Davenport (1927) reported this malignancy in 3 successive generations. The occurrence of cutaneous melanoma and intraocular melanoma as double primary cancers in the same patient and in different members of the same family has suggested that these 2 forms of melanoma may be etiologically related. From their family studies, Greene et al. (1983) concluded that these associations may be coincidental.